Developer docs
API playgroundTry for free, no card

Search company profiles

Acorda Therapeutics

Full company profile

uuid000iurx

Namestring
Acorda Therapeutics
Legal namestring
Acorda Therapeutics Inc.
Websiteurl
acorda.com
Company typeenum
Private
Founded yearint
1995
Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPearl River, United States
HQ citystring
Pearl River
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neurological therapeutics, Parkinson's disease treatment, inhalation pharmaceuticals, multiple sclerosis therapy, specialty biopharmaceuticals
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurological Pharmaceuticals
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acorda Therapeutics is a specialty biopharmaceutical company that develops and commercializes therapies for neurological disorders. Its core offering is INBRIJA, an inhaled levodopa powder indicated for the treatment of OFF episodes in patients with Parkinson's disease. The company historically also marketed Ampyra (dalfampridine) for multiple sclerosis and operated in-house packaging and manufacturing operations, which were divested to Catalent Inc.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Acorda Therapeutics is a specialty pharmaceutical company focused on neurological therapies. The company offers INBRIJA (levodopa inhalation powder), a product designed for Parkinson's disease patients experiencing OFF episodes. Historical context indicates Acorda previously operated packaging and manufacturing divisions, which were acquired by Catalent Inc., suggesting a shift toward product-focused operations rather than manufacturing infrastructure.

Product and service2 records
1INBRIJA
CategoryNeurological Pharmaceuticals
2Ampyra (dalfampridine)
CategoryNeurological Pharmaceuticals
Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Catalent Inc. acquired Acorda Therapeutics Inc.'s packaging and manufacturing divisions as part of Catalent's expansion into cell and gene therapy manufacturing capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharmaceutical company with a substantial neurology and movement disorders franchise (including Duopa for Parkinson's). Comparable in addressing Parkinson's motor symptoms, though across a much broader portfolio.

TypeBroad incumbent
Description

Global specialty CNS pharmaceutical company with a broad neurology portfolio. Comparable to Acorda as an established CNS-focused commercial organization targeting neurological disorders including Parkinson's.

TypeDirect peer
Description

Portuguese pharmaceutical company specializing in Parkinson's disease treatments (e.g., opicapone). Comparable to Acorda as a focused Parkinson's therapy developer competing in the same disease management space.

TypeBroad incumbent
Description

Specialty pharmaceutical company with significant neurology franchise (epilepsy, Parkinson's). Comparable to Acorda as a focused neurology pharma commercializing therapies for chronic CNS conditions.

TypeEmerging player
Description

Specialty CNS biopharmaceutical company developing therapies for neurological disorders. Comparable in therapeutic area focus (CNS specialty pharma) and patient population (chronic neurological conditions), though more pipeline-stage.

TypeBroad incumbent
Description

Large pharmaceutical company with a significant CNS and movement disorders franchise (including Austedo). Comparable in targeting Parkinson's and other neurology indications, though at a much larger scale.

TypeDirect peer
Description

Markets Parkinson's disease therapies in the U.S., including formulations targeting motor symptoms and OFF episodes. Comparable as a Parkinson's-focused specialty pharma competing for the same prescriber base as INBRIJA.

TypeDirect peer
Description

Acquired by Supernus Pharmaceuticals, Adamas developed Gocovri for Parkinson's disease dyskinesia, making it the most direct therapeutic competitor to Acorda's INBRIJA in the Parkinson's symptom-management market.

TypeDirect peer
Description

Specialty CNS pharmaceutical company with an established Parkinson's disease portfolio (now including Adamas assets). Directly comparable to Acorda as a focused neurology specialty pharma commercializing Parkinson's therapies.

TypeBroad incumbent
Description

Specialty neuroscience company with approved CNS therapies and a pipeline focused on neurological and endocrine disorders. Comparable as a neurology-focused commercial-stage pharma company.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acorda Therapeutics

Neurological Pharmaceuticalsacorda.com

Acorda Therapeutics firmographics

Firmographics
Name
Acorda Therapeutics
Legal name
Acorda Therapeutics Inc.
Website
https://acorda.com
Company type
Private
Founded year
1995
Operating status
Closed
Headcount range
101–250 employees
Ownership category
akta.pro rank

Acorda Therapeutics industry classification

Industry
Product category
Neurological Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurological therapeutics
  • Parkinson's disease treatment
  • Inhalation pharmaceuticals
  • Multiple sclerosis therapy
  • Specialty biopharmaceuticals

Where Acorda Therapeutics is headquartered

Location

Headquarters

HQ city
Pearl River
HQ country
United States
HQ region
North America

Markets served

Acorda Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Acorda Therapeutics product offering

Product offering

Core offering

Acorda Therapeutics is a specialty biopharmaceutical company that develops and commercializes therapies for neurological disorders. Its core offering is INBRIJA, an inhaled levodopa powder indicated for the treatment of OFF episodes in patients with Parkinson's disease. The company historically also marketed Ampyra (dalfampridine) for multiple sclerosis and operated in-house packaging and manufacturing operations, which were divested to Catalent Inc.

Product overview

Acorda Therapeutics is a specialty pharmaceutical company focused on neurological therapies. The company offers INBRIJA (levodopa inhalation powder), a product designed for Parkinson's disease patients experiencing OFF episodes. Historical context indicates Acorda previously operated packaging and manufacturing divisions, which were acquired by Catalent Inc., suggesting a shift toward product-focused operations rather than manufacturing infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

  • INBRIJA
  • Ampyra (dalfampridine)

Companies that use Acorda Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Acorda Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Acorda Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Catalent Inc.majorStrategic or Co-development PartnerCatalent Inc. acquired Acorda Therapeutics Inc.'s packaging and manufacturing divisions as part of Catalent's expansion into cell and gene therapy manufacturing capabilities.

Recent moves6 records

Expansion highlights2 records

Acorda Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Major pharmaceutical company with a substantial neurology and movement disorders franchise (including Duopa for Parkinson's). Comparable in addressing Parkinson's motor symptoms, though across a much broader portfolio.
  • Lundbeck: Global specialty CNS pharmaceutical company with a broad neurology portfolio. Comparable to Acorda as an established CNS-focused commercial organization targeting neurological disorders including Parkinson's.
  • UCB: Specialty pharmaceutical company with significant neurology franchise (epilepsy, Parkinson's). Comparable to Acorda as a focused neurology pharma commercializing therapies for chronic CNS conditions.
  • Teva Pharmaceutical Industries: Large pharmaceutical company with a significant CNS and movement disorders franchise (including Austedo). Comparable in targeting Parkinson's and other neurology indications, though at a much larger scale.
  • Neurocrine Biosciences: Specialty neuroscience company with approved CNS therapies and a pipeline focused on neurological and endocrine disorders. Comparable as a neurology-focused commercial-stage pharma company.

Direct peers

  • Bial - Portela & Cª: Portuguese pharmaceutical company specializing in Parkinson's disease treatments (e.g., opicapone). Comparable to Acorda as a focused Parkinson's therapy developer competing in the same disease management space.
  • Mitsubishi Tanabe Pharma America: Markets Parkinson's disease therapies in the U.S., including formulations targeting motor symptoms and OFF episodes. Comparable as a Parkinson's-focused specialty pharma competing for the same prescriber base as INBRIJA.
  • Adamas Pharmaceuticals: Acquired by Supernus Pharmaceuticals, Adamas developed Gocovri for Parkinson's disease dyskinesia, making it the most direct therapeutic competitor to Acorda's INBRIJA in the Parkinson's symptom-management market.
  • Supernus Pharmaceuticals: Specialty CNS pharmaceutical company with an established Parkinson's disease portfolio (now including Adamas assets). Directly comparable to Acorda as a focused neurology specialty pharma commercializing Parkinson's therapies.

Emerging players

  • Sage Therapeutics: Specialty CNS biopharmaceutical company developing therapies for neurological disorders. Comparable in therapeutic area focus (CNS specialty pharma) and patient population (chronic neurological conditions), though more pipeline-stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights4 records

Customer concentration

Acorda Therapeutics social profiles

Digital presence

Acorda Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acorda Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Acorda Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acorda Therapeutics M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acorda Therapeutics

What does Acorda Therapeutics do?

Acorda Therapeutics is a specialty biopharmaceutical company that develops and commercializes therapies for neurological disorders. Its core offering is INBRIJA, an inhaled levodopa powder indicated for the treatment of OFF episodes in patients with Parkinson's disease. The company historically also marketed Ampyra (dalfampridine) for multiple sclerosis and operated in-house packaging and manufacturing operations, which were divested to Catalent Inc.

When was Acorda Therapeutics founded?

Acorda Therapeutics was founded in 1995. It employs 101 to 250 people.

Where is Acorda Therapeutics based?

Acorda Therapeutics is headquartered in Pearl River, United States, in the North America region.

Who are Acorda Therapeutics's main competitors?

Broad incumbents on record are AbbVie, Lundbeck, UCB, Teva Pharmaceutical Industries and Neurocrine Biosciences. Direct peers are Bial - Portela & Cª, Mitsubishi Tanabe Pharma America, Adamas Pharmaceuticals and Supernus Pharmaceuticals. Sage Therapeutics is listed as an emerging player.

Does Acorda Therapeutics have an API?

No public API is recorded for Acorda Therapeutics.

What industry is Acorda Therapeutics in?

Acorda Therapeutics's product category is Neurological Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DrugPatentWatchThe Myth of the Stable Drug Patent: Why IPRs Change the Game OvernightThe article details how the U.S. Patent and Trademark Office (USPTO) reversed its inter partes review (IPR) policies in 2025 and 2026, centralizing institution decisions under the Director and causing a 43% drop in petition acceptance rates. It contrasts this recent regulatory shift with historical data showing IPRs significantly reduced branded drug revenues by a median of 79% after patent invalidation between 2012 and 2021. The piece also highlights specific corporate impacts, including stock volatility for Acorda Therapeutics and legal battles involving Celgene over Revlimid patents.DrugPatentWatchSue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug PatentsThe article analyzes the strategic and financial advantages for generic drug developers who proactively challenge weak method-of-use patents rather than waiting for expiration. It highlights specific legal victories by companies like Mylan against Biogen's Tecfidera and Acorda's Ampyra, demonstrating how early litigation can significantly compress patent exclusivity periods. The piece also discusses recent judicial precedents, such as the Supreme Court's decision in Hikma v. Amarin, which clarify the risks associated with skinny-label design-arounds.WikipediaErich Spangenberg: Difference between revisionsErich Spangenberg, an American entrepreneur and former attorney known for patent assertion activities, co-founded the Coalition for Affordable Drugs (CFAD) in 2015 with Kyle Bass of Hayman Capital Management, using the inter partes review process to challenge pharmaceutical patents while affiliated funds took short positions in target companies' stock. CFAD filed 33 patent challenges against 28 pharmaceutical companies including Celgene, Biogen, Acorda Therapeutics, and Jazz Pharmaceuticals, with the PTAB invalidating two Celgene patents in October 2016, though Bloomberg Law characterized the overall campaign as a failed attempt to lower drug prices. Spangenberg also founded IP Navigation Group (IPNav), which The New York Times reported had sued at least 1,600 companies for patent infringement, and later established ventures including IPwe and SIM IP, with IPwe filing for Chapter 11 bankruptcy in January 2024.Law360Acorda Can't Add $66M To Award In Ampyra Royalty FightThe Second Circuit on Wednesday refused to alter an arbitral award to allow Acorda Therapeutics to add nearly $66 million beyond the $16.6 million it won in a multiple sclerosis drug dispute over Ampyra royalties. The court rejected Acorda's attempt, saying the company "slept on its rights" and could not change the arbitration result after the fact. This decision closes off an avenue for Acorda to recover additional royalties in the dispute.The Pharma LetterMerz bets on China Parkinson’s market with Kvvit licensing dealMerz Therapeutics signed an exclusive licensing and collaboration agreement with Kvvit Pharmaceutical for Inbrija (levodopa) in mainland China, Hong Kong, and Macao. Kvvit will handle local development, regulatory submissions, and commercialization, while Merz retains manufacturing and quality oversight. Financial terms were not disclosed, but the deal includes upfront, development, and commercial milestone payments plus tiered royalties.Market Research & Business IntelligenceFormulation Development Outsourcing MarketThe global formulation development outsourcing market is projected to grow from USD 40.9 billion in 2025 to USD 82.0 billion by 2035, representing a compound annual growth rate of 7.2% over the forecast period. Formulation development services dominate with a 65% market share, while oral formulations lead the formulation type segment at 58% share. Key recent developments include Catalent Inc.'s acquisitions of MaStherCell Global Inc. and Acorda Therapeutics Inc.'s packaging and manufacturing divisions, as well as Quotient BioSciences' acquisition of Arcinova.PR NewswireINBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsightDelveInsight published a market report highlighting INBRIJA's growth potential as an inhaled levodopa therapy for OFF episodes in Parkinson's disease, with approximately 3 million diagnosed prevalent cases across the 7MM in 2024 and a market valued at USD 3.5 billion that is forecast to grow through 2034. Acorda Therapeutics developed INBRIJA, which received FDA approval in December 2018 and European Commission approval in September 2019, while Esteve Pharmaceuticals launched the therapy in Germany in mid-2022 and Spain in March 2023. The drug faces market challenges including high cost compared to traditional levodopa treatments and competition from emerging Parkinson's therapies in development.AbilitymagazineMS Drug — Ampyra: A New Gait For IndependenceThe FDA approved AMPYRA (dalfampridine) extended-release tablets in January 2010 to improve walking in multiple sclerosis patients. Clinical trials showed faster walking speeds versus placebo, and the drug temporarily covers demyelinated nerve areas. Acorda Therapeutics plans a March launch with specialty pharmacy distribution.AETOSWireMerz Enters Asset Purchase Agreement With a US-Based Biotech CompanyMerz Therapeutics entered an asset purchase agreement to acquire two commercial medicines from Acorda Therapeutics, a NASDAQ-listed company. The purchase price is $185 million, with closing expected in June 2024 under a court-structured 363 sale process. This marks Merz's second investment in a NASDAQ company in over ten years.BenzingaWhy Acorda Therapeutics Stock Is Down Nearly 90%Acorda Therapeutics Inc filed for Chapter 11 bankruptcy protection and entered into an asset purchase agreement with Merz Therapeutics to sell most of its assets, including rights to drugs like INBRIJA, AMPYRA, and FAMPYRA, for $185 million, causing its stock to drop approximately 75% to $3.34. The company says the decision follows a strategic review and aims to ensure uninterrupted medication supply to patients with multiple sclerosis and Parkinson's disease, with operations continuing during the sale process. Acorda canceled its fourth quarter and year-end 2023 earnings conference call but still plans to file its Annual Report on Form 10-K as scheduled.